|
|
|
|
|
|
|
|
|
13.05.25 - 00:27
|
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results (Business Wire)
|
|
|
Announced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments, plus tiered royalties on potential net sales.
Announced derisking milestones in pathway to anticipated biologics license application (BLA) submission for isaralgagene civaparvovec in Fabry disease, including all patients having passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway, and productive Type B Chemistry, Manufacturing and Controls (CMC) meeting with FDA.
Announced participation at 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, including platform presentation in prestigious Presidential Symposium to showcase nonclinical proof of concept in prion disease.
Announced pricing of $23 million underwritten registered direct equ...
|
|
|
13.05.25 - 00:27
|
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering (Business Wire)
|
|
|
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase 34,398,393 shares of its common stock, together with accompanying warrants to purchase 46,633,393 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.50. The combined offering price of each pre-funded warrant and accompanying warrant is $0.49. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $0.75 per share, will become exercisable six months from the date of issuance and will expire six years from the date of issuance. All of the securities in the offering are to be sold by Sangamo. The offerin...
|
|
|
12.05.25 - 22:03
|
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day (Business Wire)
|
|
|
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025.
The registration and access link previously provided remains the same.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference call, accessible under Events.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to trans...
|
|
|
06.05.25 - 22:39
|
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call (Business Wire)
|
|
|
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12, 2025.
The company will hold a conference call at 4:30 p.m. Eastern on Monday, May 12, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events.
A replay will be available following the conference ...
|
|
|
|
|
28.04.25 - 22:33
|
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire)
|
|
|
One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted nine Sangamo abstracts for presentation at the 28th ASGCT Annual Meeting being held May 13-17, 2025, in-person in New Orleans, LA and in a virtual format. Presentations will highlight the progression of Sangamo's neurology pipeline, including advances in zinc finger epigenetic regulation, the latest innovations in capsid delivery engineering, and developments in modular integrase technology.
“We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurolo...
|
|
|
04.04.25 - 15:45
|
Sangamo BioSciences Aktie: Diese Vorauszahlung ist enorm wichtig! (Aktiencheck)
|
|
|
Kulmbach (www.aktiencheck.de) - Sangamo BioSciences-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie von Sangamo BioSciences Inc. (ISIN: US8006771062, WKN: 936386, Ticker-Symbol: GBY, NASDAQ-Symbol: SGMO) unter die Lupe. [mehr]...
|
|
|
04.04.25 - 14:54
|
Sangamo-Aktie schießt hoch: Deal mit Eli Lilly – die Details (Der Aktionaer)
|
|
|
Mit einem Plus von gut 20 Prozent gehört die Aktie der Biotech-Gesellschaft Sangamo Therapeutics am Freitag zu den wenigen Aktien an der Börse, die mit einem sehr deutlichen Kursaufschlag gehandelt werden. Das Unternehmen hat eine weitere Zusammenarbeit mit einem namhaften Pharma-Konzern unter Dach und Fach bringen können....
|
|
|
|
|
|
|
|
|
|
|
|
|
17.03.25 - 21:03
|
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
|
|
|
Continued to advance our prioritized neurology genomic medicine pipeline towards the clinic.
Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and capsid delivery license agreement with Genentech in August 2024 to develop novel genomic medicines for neurodegenerative diseases and a capsid license agreement with Astellas in December 2024 to deliver genomic medicines for up to five neurological disease targets.
Raised over $100 million in funding in 2024 through non-dilutive license fees and milestone payments, as well as equity financing.
Investigational new drug (IND) application cleared by U.S. Food and Drug Administration (FDA) for ST-503 for treatment of intractable pain due to idiopathic small fiber neuropathy (iSFN), a type of chronic neuropathic pain. Expect to commence patient enrollment and dosing in mid-2025.
Demonstrated nonclinical proof of concept in prion disease. A single intravenous infusion of Sangamo's zinc finger repress...
|
|
|
|
|
06.03.25 - 22:09
|
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference (Business Wire)
|
|
|
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference.
Fourth Quarter and Full Year 2024 Earnings Results
The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates.
Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
